Esomeprazole Compared With Famotidine in the Prevention of Upper Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome or Myocardial Infarction

Ng, Fook-Hong; Tunggal, Prabowo; Chu, Wai-Ming; Lam, Kwok–Fai; Li, Andrew; Chan, Kit; Lau, Yuk-Kong; Kng, Carolyn; Keung, Kin Kwan; Kwan, Ambrose; Wong, Benjamin Chun–Yu

doi:10.1038/ajg.2011.385

Cited by 52 publications

(56 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Esomeprazole reduces the occurrence of peptic ulcers in patients taking LDA [122], and esomeprazole was superior to famotidine in preventing upper GI complications related to LDA, clopidogrel, and thrombolytics [123]. Famotidine was effective in the prevention of new gastric and duodenal ulcers compared to placebo in patients on LDA without ulcers on endoscopy at baseline [124].…”

Section: Commentmentioning

confidence: 88%

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology (JSGE) revised the evidence-based clinical practice guidelines for peptic ulcer disease in 2014 and has created an English version. The revised guidelines consist of seven items: bleeding gastric and duodenal ulcers, Helicobacter pylori (H. pylori) eradication therapy, non-eradication therapy, drug-induced ulcer, non-H. pylori, non-nonsteroidal anti-inflammatory drug (NSAID) ulcer, surgical treatment, and conservative therapy for perforation and stenosis. Ninety clinical questions (CQs) were developed, and a literature search was performed for the CQs using the Medline, Cochrane, and Igaku Chuo Zasshi databases between 1983 and June 2012. The guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Therapy is initially provided for ulcer complications. Perforation or stenosis is treated with surgery or conservatively. Ulcer bleeding is first treated by endoscopic hemostasis. If it fails, surgery or interventional radiology is chosen. Second, medical therapy is provided. In cases of NSAID-related ulcers, use of NSAIDs is stopped, and anti-ulcer therapy is provided. If NSAID use must continue, the ulcer is treated with a proton pump inhibitor (PPI) or prostaglandin analog. In cases with no NSAID use, H. pylori-positive patients receive eradication and anti-ulcer therapy. If first-line eradication therapy fails, second-line therapy is given. In cases of non-H. pylori, non-NSAID ulcers or H. pyloripositive patients with no indication for eradication therapy, non-eradication therapy is provided. The first choice is PPI therapy, and the second choice is histamine 2-receptor antagonist therapy. After initial therapy, maintenance therapy is provided to prevent ulcer relapse.

show abstract

Section: Commentmentioning

confidence: 88%

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

View full text Add to dashboard Cite

show abstract

“…After subtracting duplications/ triplications (18/8), 214 articles were excluded after reading their title and abstract (174) or full text (46), due to exclusion criteria or to missing inclusion criteria. Six articles fulfilled all criteria [28][29][30][31][32][33]. One systematic review [34] checked during the assessment cited six additional Chinese papers fulfilling inclusion criteria and showed data suitable for comparison.…”

Section: Resultsmentioning

confidence: 99%

PPIs Prevent Aspirin-Induced Gastrointestinal Bleeding Better than H2RAs. A Systematic Review and Meta-analysis

Szabó¹,

Mátics

Hegyi

et al. 2017

JGLD

View full text Add to dashboard Cite

Background & Aims: Aspirin is one of the most widely used medication for its analgesic and anti-platelet properties and thus a major cause for gastrointestinal (GI) bleeding. This study compared the preventive effect of histamine-2 receptor antagonists (H2RAs) and proton-pump inhibitors (PPIs) against chronic low-dose aspirin (LDA)-related GI bleeding and ulcer formation.Methods: Electronic databases of Pubmed, Embase and Cochrane Central Register of Controlled Trials were searched for human observations (randomised controlled trials and observational studies) comparing the long term effects of PPIs and H2RAs treatment in the prevention of GI bleeding or ulcer formation in patients on chronic LDA treatment listed up till September 30, 2016. Two independent authors searched databases using PICO questions (aspirin, H2RA, PPI, GI bleeding or ulcer), and reviewed abstracts and articles for comprehensive studies keeping adequate study quality. Data of weighted odds ratios were statistically evaluated using Comprehensive Metaanalysis (Biostat, Inc., Engelwood, MJ, USA), potential bias was checked.Results: Nine studies for GI bleeding and eight studies for ulcer formation were found meeting inclusion criteria, altogether 1,879 patients were included into review. The H2RAs prevented less effectively LDA-related GI bleeding (OR= 2.102, 95% CI: 1.008-4.385, p<0.048) and ulcer formation (OR= 2.257, 95% CI: 1.277-3.989, p<0.005) than PPIs.Conclusion: The meta-analysis showed that H2RAs were less effective in the prevention of LDA-related GI bleeding and ulcer formation suggesting the preferable usage of PPIs in case of tolerance.Abbreviations: COX -1: cyclooxygenase-I enzyme; COX-2: cyclooxygenase-II enzyme; GI: gastrointestinal; H2RA(s): histamine-2 receptor antagonist(s); H. pylori: Helicobacter pylori; LDA: low dose aspirin; NSAID(s): non-steroid anti-inflammatory drug(s); OR: Odds ratio; PPI(s): proton-pump inhibitor(s); RCT: randomized controlled trial; RR: relative risk; UGIB: upper gastrointestinal bleeding.

show abstract

“…ИПП превосходили Н 2 -блокаторы на фоне приема традицион-ных НПВП (ОШ 0,13 при 95% ДИ от 0,09 до 0,19 против ОШ 0,30 при 95% ДИ от 0,17 до 0,53) и низких доз АСК (ОШ 0,32 при 95% ДИ от 0,22 до 0,51 против ОШ 0,40 при 95% ДИ от 0,19 до 0,73) [24]. У пациентов с острым коронарным синдромом или инфар-ктом миокарда (ИМ) с подъемом сегмента ST ИПП в дозе 20 мг/сут превосходил фамотидин в дозе 40 мг/сут в профилактике ЖКО, связанных приемом с АСК, клопидогрела, эноксапарина или тромболитиков [41].…”

Section: терапевтический архив 12 2014unclassified

Antiplatelet therapy with acetylsalicylic acid: Approaches to reducing the frequency of gastrointenstinal adverse reactions

Ev¹

2014

Ter. arkh.

View full text Add to dashboard Cite

Антитромбоцитарная терапия (АТТ) ингибитором синтеза тромбоксана А 2 -ацетилсалициловой кислотой (АСК) -высоко эффективна для профилактики сердечно-сосудистых осложне-ний (ССО). Между тем снижение риска развития кардиологиче-ских событий достигается путем повышения вероятности неже-лательных реакций со стороны органов пищеварения.Прием АСК традиционно связывают с поражением прокси-мальных отделов (ПО) желудочно-кишечного тракта (ЖКТ). При длительной терапии низкими дозами АСК частота развития симптомов диспепсии достигает 15-40% [1], эрозивного эзофа-гита -7,9-22%, язв пищевода -0,9% [2,3], эрозий желудка и/ или двенадцатиперстной кишки (ДПК) -34-63,1% [4,5], язв желудка и/или ДПК -10-40% [6]. Относительный риск (ОР) желудочно-кишечных кровотечений (ЖКК) варьирует, по расче-там различных авторов, в пределах от 2,4 до 7,7 [7,8]. Показатель выше в случаях приема АСК для первичной по сравнению с вто-ричной профилактикой ССО [9].Между тем благодаря внедрению в клиническую практику новых методов диагностики появились сведения о поражении АСК дистальных отделов (ДО) пищеварительного тракта. Назна-чение АСК в дозе 100 мг/сут здоровым добровольцам привело через 2 нед к повреждению слизистой оболочки (СО) тонкой АннотацияПрием ацетилсалициловой кислоты (АСК) высокоэффективен для профилактики сердечно-сосудистых осложнений, но сопряжен с повышением вероятности нежелательных явлений со стороны органов пищеварения. В статье представлены современные данные по эпидемиологии, механизмам развития и факторам риска эзофагогастродуодено-и энтеропатий на фоне длительной терапии низкими дозами АСК. Изложены ключевые принципы их профилактики. Ключевые слов: ацетилсалициловая кислота, ингибиторы протонной помпы, эрадикационная терапия.Acetylsalicylic acid (ASA) is highly effective in preventing cardiovascular events, but associated with increased risk for digestive adverse reactions. The paper provides an update on the epidemiology, mechanisms, and risk factors of esophagogastroduodenoand enteropathies during long-term low-dose ACA therapy. It outlines the key principles of their prevention. Key words: acetylsalicylic acid, proton pump inhibitors, eradication therapy.ИМ -инфаркт миокарда НПВП -нестероидные противовоспалительные препараты ОР -относительный риск ОШ -отношение шансов ПО -проксимальные отделы РКИ -рандомизированное клиническое исследование СО -слизистая оболочка ССО -сердечно-сосудистые осложнения ЦОГ-1 -циклооксигеназа-1 ЯБ -язвенная болезнь кишки, визуализированному с помощью капсульной эндоско-пии, в 50% случаев. По сравнению с исходным уровень фекаль-ного кальпротектина (показателя, коррелирующего с гистологи-ческой и эндоскопической активностью воспаления стенки киш-ки) повысился в 4 раза, а коэффициента лактулоза/маннитол (теста на проницаемость кишечной стенки, отражающего ба-рьерную функцию кишечной стенки) -в 1,7 раза [10]. Применяя капсульную эндоскопию для уточнения происхождения ЖКК и/ или болевого абдоминального синдрома у лиц, получавших низ-кие дозы АСК более 3 мес, H. Endo и соавт.[11] в 63,6% случаев выя...

show abstract

Esomeprazole Compared With Famotidine in the Prevention of Upper Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome or Myocardial Infarction

Abstract: In patients with ACS or STEMI, esomeprazole is superior to famotidine in preventing upper gastrointestinal complications related to aspirin, clopidogrel, and enoxaparin or thrombolytics.

Cited by 52 publications

References 32 publications

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

PPIs Prevent Aspirin-Induced Gastrointestinal Bleeding Better than H2RAs. A Systematic Review and Meta-analysis

Antiplatelet therapy with acetylsalicylic acid: Approaches to reducing the frequency of gastrointenstinal adverse reactions

Contact Info

Product

Resources

About